XML 105 R89.htm IDEA: XBRL DOCUMENT v3.24.0.1
Contingent Liabilities, Commitments, Claims and Liens (Details) - USD ($)
$ in Thousands
12 Months Ended
Jul. 27, 2022
Dec. 02, 2021
Aug. 11, 2020
Nov. 13, 2019
Apr. 11, 2017
Dec. 31, 2022
Contingent Liabilities Commitments Claims and Liens [Abstract]            
Dekel license agreement, description           (i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company’s discretion, the respective milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would likely be 2029.
Annual investment           $ 350
Additional milestone amount       $ 75    
Installment amount         $ 122  
Total estimated amount $ 370 $ 1,385     $ 776  
Capital proposed to deposit     $ 1,500